|
1
|
Pui CH, Mullighan CG, Evans WE and Relling
MV: Pediatric acute lymphoblastic leukemia: where are we going and
how do we get there? Blood. 120:1165–1174. 2012. View Article : Google Scholar
|
|
2
|
Marks DI: Treating the ‘older’ adult with
acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ
Program. 2010:13–20. 2010.
|
|
3
|
Colvin GA and Elfenbein GJ: The latest
treatment advances for acute myelogenous leukemia. Med Health R I.
86:243–246. 2003.PubMed/NCBI
|
|
4
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER
Cancer Statistics Review, 1975–2010. National Cancer Institute;
Bethesda, MD: http://seer.cancer.gov/csr/1975_2010/,
based on November 2012 SEER data submission, posted on the SEER
website, 2013.
|
|
5
|
Fausel C: Targeted chronic myeloid
leukemia therapy: seeking a cure. Am J Health Syst Pharm.
64:S9–S15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mathers CD, Boschi-Pinto C, Lopez AD and
Murray CJL: Cancer incidence, mortality and survival by site for 14
regions of the world. Global Programme on Evidence for Health
Policy Discussion Paper No. 13. World Health Organization; 2001
|
|
7
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
8
|
Polychronakis I, Dounias G, Makropoulos V,
Riza E and Linos A: Work-related leukemia: a systematic review. J
Occup Med Toxicol. 8:142013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao H, Wang D, Du W, Gu D and Yang R:
MicroRNA and leukemia: tiny molecule, great function. Crit Rev
Oncol Hematol. 74:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M,
Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C,
Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and
Croce CM: A MicroRNA signature associated with prognosis and
progression in chronic lymphocytic leukemia. N Engl J Med.
353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy
CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V,
Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD,
Byrd JC, Chan K, Wu LC, Croce CM and Marcucci G: MicroRNA-29b
induces global DNA hypomethylation and tumor suppressor gene
reexpression in acute myeloid leukemia by targeting directly DNMT3A
and 3B and indirectly DNMT1. Blood. 113:6411–6418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bueno MJ, Pérez de Castro I, Gómez de
Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM,
Fernández-Piqueras J and Malumbres M: Genetic and epigenetic
silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene
expression. Cancer Cell. 13:496–506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pekarsky Y, Santanam U, Cimmino A,
Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG,
Rassenti L, Calin GA, Hagan JP, Kipps T and Croce CM: Tcl1
expression in chronic lymphocytic leukemia is regulated by miR-29
and miR-181. Cancer Res. 66:11590–11593. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nie K, Gomez M, Landgraf P, Garcia JF, Liu
Y, Tan LH, Chadburn A, Tuschl T, Knowles DM and Tam W:
MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in
Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in
Hodgkin lymphomas. Am J Pathol. 173:242–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gefen N, Binder V, Zaliova M, Linka Y,
Morrow M, Novosel A, Edry L, Hertzberg L, Shomron N, Williams O,
Trka J, Borkhardt A and Izraeli S: Hsa-mir-125b-2 is highly
expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and
confers survival advantage to growth inhibitory signals independent
of p53. Leukemia. 24:89–96. 2010. View Article : Google Scholar
|
|
18
|
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z,
Li P, Zhang W, Wu H, Feng N, Wang Z, Hua L and Wang X: miR-143
decreases prostate cancer cells proliferation and migration and
enhances their sensitivity to docetaxel through suppression of
KRAS. Mol Cell Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akao Y, Nakagawa Y, Kitade Y, Kinoshita T
and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell
malignancies. Cancer Sci. 98:1914–1920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen HC, Chen GH, Chen YH, Liao WL, Liu
CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and
pathway alterations in nasopharyngeal carcinoma. Br J Cancer.
100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wijnhoven BP, Hussey DJ, Watson DI, Tsykin
A, Smith CM and Michael MZ: MicroRNA profiling of Barrett’s
oesophagus and oesophageal adenocarcinoma. Br J Surg. 97:853–861.
2010.
|
|
23
|
Takagi T, Iio A, Nakagawa Y, Naoe T,
Tanigawa N and Akao Y: Decreased expression of microRNA-143 and
-145 in human gastric cancers. Oncology. 77:12–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S
and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a
in non small cell lung cancer is related to clinicopathologic
characteristics or patient prognosis. Biomed Pharmacother.
64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Cai X, Wang Y, Tang H, Tong D and
Ji F: microRNA-143, down-regulated in osteosarcoma, promotes
apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol
Rep. 24:1363–1369. 2010.PubMed/NCBI
|
|
26
|
Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li
JJ, Röcken C, Ebert MP, Kwok TT and Sung JJ: MicroRNA-143 targets
DNA methyltransferases 3A in colorectal cancer. Br J Cancer.
101:699–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh
T, Kojima K, Nakashima R, Kitade Y and Naoe T: Role of
anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer
Gene Ther. 17:398–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kiyota M, Kuroda J, Yamamoto-Sugitani M,
Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N,
Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S and Taniwaki M:
FTY720 induces apoptosis of chronic myelogenous leukemia cells via
dual activation of BIM and BID and overcomes various types of
resistance to tyrosine kinase inhibitors. Apoptosis. 18:1437–1446.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dick FR, Armitage JO and Burns CP:
Diagnostic concurrence in the subclassification of adult acute
leukemia using French-American-British criteria. Cancer.
49:916–920. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Batliner J, Buehrer E, Fey MF and Tschan
MP: Inhibition of the miR-143/145 cluster attenuated neutrophil
differentiation of APL cells. Leuk Res. 36:237–240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Slaby O, Svoboda M, Fabian P, Smerdova T,
Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered
expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology.
72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, -143 and -145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Clape C, Fritz V, Henriquet C, Apparailly
F, Fernandez PL, Iborra F, Avancès C, Villalba M, Culine S and
Fajas L: miR-143 interferes with ERK5 signaling, and abrogates
prostate cancer progression in mice. PLoS One. 4:e75422009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Zhang SZ, Cai SR, Peng JP and Zheng
S: Effect of microRNA143 expression on cell proliferation in
colonic carcinoma. Zhonghua Zhong Liu Za Zhi. 30:498–501. 2008.(In
Chinese).
|
|
35
|
Akao Y, Nakagawa Y, Iio A and Naoe T: Role
of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia
Jurkat cells. Leuk Res. 33:1530–1538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Robertson KD and Wolffe AP: DNA
methylation in health and disease. Nat Rev Genet. 1:11–19. 2000.
View Article : Google Scholar
|
|
37
|
Shen L and Pili R: Posttranscription
regulation of prostate cancer growth. Cancer J. 14:46–53. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Smith EM, Boyd K and Davies FE: The
potential role of epigenetic therapy in multiple myeloma. Br J
Haematol. 148:702–713. 2010. View Article : Google Scholar : PubMed/NCBI
|
